Corvus Pharmaceuticals Inc

NASDAQ: CRVS
$1.44
+$0.04 (+2.9%)
Closing price April 22, 2024
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is headquartered in Burlingame, California.
Tuesday's top analyst upgrades and downgrades included Applied Materials, Bill, Catalyst Pharmaceutical, CVS Health, Elastic, Hawaiian Electric Industries and Walmart.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
Wednesday afternoon's analyst upgrades and downgrades included American Water Works, Corvus Pharmaceuticals, ImmunoGen, Lennar, StoneCo and Vertex Energy.
Wednesday's top analyst upgrades and downgrades included Akamai Technologies, Avaya, Canopy Growth, Corsair Gaming, Skyworks Solutions and Virgin Galactic.